Global Thalassemia Market Report: 2016 Edition - New Report by Koncept Analytics - PowerPoint PPT Presentation

Loading...

PPT – Global Thalassemia Market Report: 2016 Edition - New Report by Koncept Analytics PowerPoint presentation | free to download - id: 81a215-NTE4N



Loading


The Adobe Flash plugin is needed to view this content

Get the plugin now

View by Category
About This Presentation
Title:

Global Thalassemia Market Report: 2016 Edition - New Report by Koncept Analytics

Description:

The Global Thalassemia Market report provides a comprehensive study of global thalassemia market and also major regional markets. For more mail: vikas@konceptanalytics.com – PowerPoint PPT presentation

Number of Views:18

less

Write a Comment
User Comments (0)
Transcript and Presenter's Notes

Title: Global Thalassemia Market Report: 2016 Edition - New Report by Koncept Analytics


1
Global Thalassemia Market Report
----------------------------------------- 2016
View Report Details
2
View Report Details
  • Executive Summary
  • Thalassemia is a hereditary blood disorder in
    which a persons body makes an abnormal form of
    hemoglobin, which is the protein molecule in red
    blood cells (RBCs), which carries oxygen. The
    disorder results in unwarranted damage of red
    blood cells, which leads to anemia. Anemia is a
    condition in which the body doesnt have adequate
    amount of normal and healthy red blood cells.
    There are majorly two types of thalassemia based
    on these proteins known as the Alpha thalassemia
    and the Beta thalassemia. There is also a third
    type viz. Sickle beta thalassemia, which is like
    a combination of sickle cell disease and beta
    thalassemia.
  • Even though it is a rare genetic disorder, the
    number of people affected by it has been growing
    with time. While those with thalassemia minor
    have hardly any threat to their life and only
    require occasional blood transfusion to sustain,
    thalassemia major patients need to go for
    periodic transfusions for a sustained life. In
    case of infants, thalassemia major often leads to
    still birth or cause death shortly after the
    babys birth. Presently the only cure for
    thalassemia is a bone marrow transplantation
    therapy, which is done mostly for severe cases of
    thalassemia.
  • The key factors which are anticipated to drive
    this market include rising healthcare
    expenditure, rising spending on stem cell therapy
    research and development and rising population in
    the East-Asia and Pacific region of the world.
    Some of the noteworthy progresses of this
    industry include the advances in the iron
    chelation therapy, development of gene therapy
    and fetal hemoglobin inducers as potential
    curatives for thalassemia. However, the growth of
    respective industry is challenged by the high
    cost of treatments, lack of alternative
    treatments and unmet market of the Asia-Pacific.
  • The report provides a comprehensive study of
    global thalassemia market and also major regional
    markets. Furthermore, market dynamics such as key
    trends and development and challenges are
    analyzed in depth. The global thalassemia
    industry is highly competitive consisting of
    several companies including the Lonza group,
    Acceleron Pharma, BlueBird Bio and Sangamo
    Biosciences etc. The competitive landscape of the
    respective market, along with the company
    profiles of the leading players are also
    discussed in detail.

3
Bone marrow transplantation is presently the only
chief cure for thalassemia major patients or
patients with transfusion-dependent thalassemia
Global Thalassemia Diagnosis by Category (2015E)
  • It is noted that out of the total people
    suffering from severe thalassemia, only xx cases
    are estimated to be diagnosed with thalassemia
    major non-ß0/ß0 type, while xx cases are
    diagnosed with phenotypical ß0/ß0 type of
    thalassemia.
  • It is estimated that in the year 2015, nearly
    xx.xx of the global transfusion-dependent ß
    thalassemia patients were from the Middle-East
    region and xx.x were from the South-East Asian
    region.
  • The global bone marrow transplant therapy revenue
    is estimated to be USxx.xx billion for the year
    2015. It is estimated to grow at a CAGR of xx
    over the next five years and is forecasted to
    reach USxxx by the end of the year 2020.


Global Transfusion-Dependent ß Thalassemia by
Region (2015E)
Global Bone Marrow Transplant Revenue
(2015E-2020F)
4
Transfusion-dependent patients are those whose
level of severity of disease is so high that
regular blood transfusions have to be conducted
for a sustained life and healthy functioning of
these patients.
The US ß Thalassemia Carrier Patients Forecast
(2016F-2020F)
  • The number of beta thalassemia carriers in the US
    is estimated to have reached . thousand in the
    year 2015. The number is expected to grow further
    in the future years, and is forecasted to grow at
    a CAGR of xx over the period 2016-2020
  • The number of beta thalassemia major patients for
    the year 2014 in the US is noted to be xx.x
    thousand and is estimated to have reached xx
    thousand in the year 2015, marking a slight
    growth of xx.
  • It is forecasted that the number of
    transfusion-dependent ß thalassemia patients in
    the US will rise gradually over time, reaching a
    total of xx thousand patients by the end of the
    year 2020.

The US Transfusion-Dependent ß Thalassemia
Patients (2016F-2020F)
The US ß Thalassemia Major Patients Forecast
(2016F-2020F)
5
The most effective type and also the most hard to
find is the sibling-matched bone marrow
transplant.
The US ß Thalassemia Sibling-Matched Stem Cell
Transplant (2016F-2020F)
  • It is forecasted that the number of patients
    taking sibling-matched stem cell transplant among
    ß thalassemia patients in the US will reach a sum
    of xx0 thousand persons by the year 2020.
  • It is forecasted that the number of
    transfusion-dependent ß thalassemia patients in
    the Europe will increase further at a CAGR of xx
    over the period 2016-2020, thereby reaching a sum
    of xxx thousand patients by the end of the year
    2020.
  • Out of the total number of transfusion-dependent
    ß thalassemia patients in the Europe, it is
    estimated that nearly xxx thousand patients are
    those with major/intermediate level of severity,
    in the year 2015.

Europe Transfusion-Dependent ß Thalassemia Major
Patients
Europe Transfusion-Dependent ß Thalassemia
Patients
6
Contact Us
View Report Details
These are abridged and sanitized sample pages
from the comprehensive report on the Global
Thalassemia Market . To know more about this
report or for any customized research
requirement, please contact the following
Koncept Analytics CS-36, Second Floor, Ansal
Plaza Vaishali, Ghaziabad, U.P. 201010 T.
91-120-4130959 C 91-9811715635
vikas_at_konceptanalytics.com
Vikas Gupta BD Manager
www.konceptanalytics.com
About PowerShow.com